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• Single-centre study of 254 patients with esophageal adenocarcinoma. 
• Pre and postoperatively variables models were studied for 
prognostication. 
• Histopathological N-stage and tumor length were good prognostic factors.  
• Age and preoperative radiological staging, were not associated with 
prognosis. 
• Histopathological T-stage may be of less importance for prognostication. 
 
Abstract 
Background: Prognostication for esophageal cancer has traditionally relied on 
postoperative tissue specimens. This study aimed to use a histologically 
homogenous cohort to investigate the relationship between clinical, pathological or 











Methods: A single-centre study of patients who underwent esophagectomy for 
adenocarcinoma over 10 years in a tertiary centre was performed. By regression 
analysis, variables available preoperatively and postoperatively were studied for 
prognostication. The primary outcome was overall survival. 
Results: 254 cases were analyzed. Over a median follow-up period of 31.8 
months (IQR=42.5), overall survival was 51.5 months (95% confidence interval: 
33.0-69.9). According to hazard ratios (HR) for all-cause death, adverse prognostic 
factors included: a higher postoperative N-stage (HR≥1.29; p≤0.024), 
histopathological tumor length ≥25mm (HR=2.04; p=0.03), poorer tumor 
differentiation (HR≥2.86; p≤0.042), and R1 status (HR=2.33; p=0.02). A lymph 
node yield ≥35 was a favorable prognostic factor (HR=0.022; p<0.001). 
Demographic and radiological variables, preoperative TNM stages, postoperative 
T-stage, and neoadjuvant/adjuvant treatment were not associated with overall 
survival. 
Conclusions: This study identifies several postoperatively factors which are 
available for the prognostication and identifies factors that should not be used to 
exclude patients from curative surgery. 
 









1- Introduction  
Esophageal cancer is the eighth most common malignancy worldwide, with an 
annual incidence of 450 000 cases, and is the sixth leading cause of cancer-
related mortality with more than 400 000 deaths annually[1]. Surgery is central to 
curative treatment of esophageal cancer, although only up to 50% of patients are 
suitable for curative treatment[1]. The remainder are often offered either palliative 
or best supportive treatment, which may involve chemotherapy, radiotherapy, 
immunotherapy or esophageal stenting. The 5-year overall survival (OS) is 
currently estimated at 15%, but can range from 40% (in localized cancer treated 
with curative intent) to as low as 5% (in unresectable disease)[2]. Currently, the 
prognosis for patients with esophageal cancer largely relies on postoperative 
histopathology and has been criticized as being inadequate for prognostication at 
the pre-treatment stage[3]. 
Cross-sectional imaging is routinely used for diagnosis, staging and prognosis of 
esophageal cancer. Positron emission tomography with computed tomography 
(PET-CT) is increasingly used for preoperative staging to assess for distant 
metastatic disease and it adds information on tumor metabolic activity[4]. 
In a previous work on a histologically heterogeneous cohort of 229 cases, our 
group concluded that both tumor length and SUVmax on pre-treatment PET-CT 
were associated with OS[5]. However, esophageal adenocarcinoma (OAC) and 










esophageal cancer, are separate diseases in terms of epidemiology, anatomical 
location and natural history, with implications on treatment[6]. In the current study, 
we sought to re-examine the above association, along with other 
clinicopathological variables, in a histologically homogeneous cohort. 
 
2 - Methods 
A retrospective observational study was performed. Patients who underwent 
esophagectomy at a single tertiary unit (the Norfolk & Norwich University Hospital, 
Norwich, United Kingdom) over a 10-year period (March 2007 - March 2017) were 
identified from local records. This was facilitated by the general electronic hospital 
database and the data collection was performed by the authors. Patients were 
included if they had undergone elective esophagectomy (either open, minimally 
invasive, or hybrid) for cancer with curative intent. 
The exclusion criteria were patients without a pre-treatment PET-CT, without a 
reported tumor length on PET-CT, with a tumor type other than OAC and submitted 
to palliative surgery. Patients who died within 30 days postoperatively were also 
excluded, in order to minimize the influence of early postoperative death due to 
non-oncological causes. 
The variables of interest were categorized into those which are available to the 










postoperatively. Preoperative variables included age, sex, neoadjuvant treatment 
status, tumor length (TL) and maximal standardized radioisotope uptake value 
(SUVmax) on PET-CT, and tumor-node-metastasis (TNM) stage. Postoperative 
variables included histopathological tumor length, number of lymph nodes 
retrieved, tumor differentiation (poor versus moderate/well differentiated), pTNM 
stage, resection radicality (R status), and adjuvant therapy status. The primary 
outcome was OS. All pathological specimens were pinned down on a plaque prior 
histological fixation which allowed a comparison of tumour length measurements. 
2.1 - Staging 
Standard staging practice for OAC at the Norfolk & Norwich University Hospital 
(NNUH) involves endoscopy with biopsy, thoraco-abdomino-pelvic CT scan, and 
PET-CT scan for all patients. All images are reviewed by an upper gastro intestinal 
expert radiographer in MDT. In cases of liver lesions which are not PET-avid, 
magnetic resonance imaging (MRI) of the liver is performed. Endoscopic 
ultrasonography (EUS) is employed for patients where a distinction between T4a 
and T4b tumors is required. Patients with T4b do not undergo curative resection at 
the NNUH. Patients with Siewert type-2 and type-3 tumors also undergo 
laparoscopic staging. During the study period, the NNUH Esophageal Cancer MDT 
followed the 6th and 7th editions of the Union for International Cancer Control 










for analysis were collected from the local MDT consensus electronic database and 
were reclassified to meet the 7th edition TNM criteria. 
2.2 - Analysis 
Statistical analysis was performed using IBM SPSS v.25 and STATA. Normally 
distributed variables are expressed as means with standard deviation. Non-
normally distributed variables are expressed as medians with interquartile range 
(IQR). Cox regression analysis was performed to investigate for relationships 
between variables of interest and OS (calculated from the date of surgery to the 
date of death). Three separate Cox regression analyses were performed: 1) using 
an unadjusted model which included all variables of interest, 2) using only 
preoperative variables (preoperative model), and 3) using variables which are only 
available postoperatively (postoperative model). Strongly inter-related variables 
were excluded from regression modeling. 
This retrospective study was based on data collected and available as part of 
routine clinical practice and did not involve any deviations from the standard of 
care. For the purposes of this study, data were anonymized. Formal ethical 
approval was therefore not requested, nevertheless data collection was registered 










3 - Results 
345 patients who underwent esophagectomy for cancer at the NNUH between 
March 2007 and March 2017 (inclusive) were screened for eligibility. Forty patients 
were excluded as they either did not have an available pre-treatment PET-CT (28), 
or the tumor length on pre-treatment PET-CT was not reported (12). Five patients 
were excluded as they had died within 30 postoperative days. Forty-six patients 
were excluded as their tumor type was preoperatively diagnosed as other than 
adenocarcinoma. The analysis was performed on a cohort of 254 patients, and 
follow-up was censored on the 30th of August 2018. Figure 1 presents the study 
flowchart. 
3.1 - Preoperative variables 
The median age at time of diagnosis was 67.0 years (interquartile range [IQR]= 
12.0 years). Most patients (n=211; 83.1%) were male. 81.5% (n=207) of patients 
received neoadjuvant treatment. The mean tumor length on pre-treatment PET-CT 
was 40.8mm (standard deviation [SD]=26.1mm), and the mean SUVmax was 10.1 
(SD=8.8). A detailed report of preoperative variables, including staging parameters, 
is presented in Table 1. 
3.2 - Postoperative variables 
Following esophagectomy, the mean histopathological tumor length was 










response to treatment. The mean number of lymph nodes retrieved was 25.8 
(SD=12.5). The mean number of lymph nodes positive for malignancy was 2.2 
(SD=3.9), and the mean positive-to-total lymph node ratio (LNR) was 0.086 
(SD=0.139). These variables, along with tumor differentiation, stage, resection 
radicality and adjuvant therapy status are presented in Table 2. 
3.3 - Survival analysis 
The median follow-up period was 31.8 months (IQR=42.5 months), during which 
134 patients (52.8%) died. The median estimated OS by Kaplan-Meier analysis 
was 51.5 months (95% confidence interval [CI]: 33.0-69.9 months; Figure 2). 
In the unadjusted Cox regression model, the hazard ratio (HR) for all-cause 
death was significantly increased (i.e. OS was significantly reduced) in cases with 
a histopathological tumor length of ≥25mm, poorer tumor differentiation, increasing 
postoperative T and N stages, and in patients who underwent adjuvant 
radiotherapy or with resection margins which were microscopically positive for 
malignancy (i.e. R1). Demographics, neoadjuvant therapy, PET-CT variables (TL 
and SUVmax), pre-treatment T and N stage, number of lymph nodes retrieved, and 
adjuvant chemotherapy were not associated with a significantly reduced or 
increased HR. Detailed results of the unadjusted analysis are presented in Table 3. 
In the adjusted preoperative model, the only factor significantly associated with 










In the adjusted postoperative model, OS was significantly associated with the 
number of lymph nodes retrieved ≥35 (i.e. lymph node yield [LNY]; HR=0.22; 
95%CI=0.11-0.44; p<0.001), a histopathological tumor length of ≥25mm (HR=2.04; 
95%CI=1.07-3.89; p=0.03), histopathological lymph node positivity (HRN1=1.9; 
HRN2=3.09; HRN3=4.7; p<0.025 in all cases), and with R1 status (HR=2.33; 
95%CI=1.38-3.94; p=0.002). In this model, there was no significant association 
between OS and sex, age, chemotherapy, radiotherapy, PET-CT variables, and 
postoperative T-stage. Table 4 presents the results of both adjusted models. 
 
4 - Discussion 
This study evaluated several clinicopathological variables in relation to OS for 
patients with resectable OAC. As mentioned in a recent review on staging, 
prognosis has been largely based on postoperative pathological findings, and has 
been criticized as being inadequate for patients at the pre-treatment stage or for 
those undergoing multimodal treatment[3]. The current study aimed to identify both 
preoperatively and postoperatively prognostic factors which are relevant to the 
decision-making process. It was noted that, taking into account the factors that 
were studied, it is still very difficult to accurately prognosticate this disease on a 
preoperative setting. This is due, most likely, to a great disparity of cancer 










The two main histological subtypes of esophageal cancer, SCC and OAC, have 
been identified as socioeconomically, anatomically, and biologically different 
diseases, with implications on treatment strategies and prognosis[6]. Therefore, 
and further to previous work from our group[5], patients with histological subtypes 
other than OAC were excluded from this study, in order to reduce heterogeneity. 
The median estimated OS (51.5 months) was achieved most certainly due to all 
patients included in the study having had a full oncological resection intention, 
where none of them had a palliative surgical procedure. In addition, the mean 
number of lymph nodes retrieved was 25.8 and only 15.7% of patients had R1 
resections.  
4.1 - Demographic variables 
The demographic variables of age and sex were not associated with OS in any 
of the three regression models. This is in keeping with the results published by Bus 
et al.[9], who performed a population-based study and analyzed a heterogeneous 
cohort (OAC: 62%; SCC: 37%) of 703 patients. Their multivariable regression 
analysis determined that age was not independently associated with 1-year, 3-year 
or 5-year survival. Although sex was not associated with 1-year or 3-year survival, 
it was associated with 5-year survival. Specifically, female patients were more 
likely to be alive at 5 years after diagnosis, with an odds ratio for death of 0.56 vs. 
men[9]. The median follow-up period in our study was less than 3 years (31.8 










of OS. On this basis, it could be concluded that, within the range observed in this 
study, age per se should not be a contraindication to curative surgery, or 
multimodal treatment for resectable OAC. 
4.2 - Radiological variables 
The potential role of PET-CT in identifying patients for curative vs. palliative 
treatment was reported in a small cohort (n=82), including the following variables: 
tumor length, SUVmax, and the length-SUV index (tumor length x SUVmax)[10]. 
Although the authors conclude that tumor length on PET-CT is associated with 
OS[10], the proportion of patients with OAC in this cohort is not specified. In our 
previous heterogeneous cohort, PET-CT tumor length was associated with OS[5], 
which is in keeping with the conclusions mentioned by Roedl et al[10]. Our current 
analysis on a homogeneous OAC cohort however, did not demonstrate an 
association PET-CT tumor length and OS. This may be due to a more aggressive 
behavior of longer esophageal SCC when compared to OAC or the fact that SCC 
tumors present less response variability with neoadjuvant treatment. 
SUVmax is a standard measure of radioisotope (18F-fluorodeoxyglucose; 18F-
FDG) uptake by esophageal tumor and represents metabolic activity[4]. It is 
defined as the activity concentration in tissue divided by the activity injected per 
unit body weight[4]. With regards to SUVmax and survival, the evidence[4, 5, 11, 12] 
appears to be conflicting. For example, in their study of 103 esophageal cancer 










found SUVmax to be a significant factor in univariate, but not in multivariate 
analysis. They recognized that tumors such as adenocarcinoma yield lower 
SUVmax values, which may be responsible for the negative result[13]. Furthermore, 
the cohort examined by Foley et al. included 68 patients treated with curative intent 
and 35 treated with palliative intent. Our analysis identified SUVmax as predictor of 
OS only in the adjusted preoperative model. The reasons for this inconsistency are 
unclear but may involve less confounding factors on the preoperative model data 
when compared with the unadjusted model. Nonetheless SUVmax measurements 
are known to involve several pitfalls, such as a lack of standardization in their 
calculation, and variation in the timing of FDG administration[4]. Furthermore, PET-
CT image reconstruction techniques can render lesions larger and less bright, thus 
leading to SUVmax underestimations[4]. 
4.3 - TNM staging 
The Union for International Cancer Control (UICC) regularly publishes updates 
on the TNM (tumor-node-metastasis) Classification of Malignant Tumors, a widely 
implemented cancer staging tool. During the period of this study, the 6th, followed 
by the 7th edition of the UICC TNM Classification were used. The current (8th) 
edition was published in December 2016[14], approximately three months prior to 
the end of the study period. 
The transitions from the 6th to the 7th, and subsequently to the 8th edition have 










cancer or gastric cancer schema depending on the epicenter and extent of the 
tumor[14]. By design, the T, N, and M stages should be reproducible and should 
allow stratification of patients into prognostic groups, whereby survival diminishes 
as the stage increases. In a validation study of the 7th edition, Talsma et al.[15] 
analyzed a cohort of 358 patients who underwent transhiatal esophagectomy for 
OAC. On univariate analysis, the authors concluded that pT, pN, and pM stages 
significantly predicted OS, and that the 7th edition provides superior prognostic 
stratification than the 6th edition[16]. The 7th edition[7] introduces 
subclassifications of T1 (i.e. T1a: Tumor invasion of the lamina propria or 
muscularis mucosae; T1b: Tumor invasion of submucosa), and a new N-stage (i.e. 
N3: metastasis in ≥7 regional lymph nodes). 
The first significant observation in our cohort is that all patients had M0 stage, as 
patients with metastatic OAC do not undergo surgery with curative intent in NNUH. 
Also, although histologically homogeneous, our cohort was heterogeneous with 
respect to surgical approach, as patients may have either undergone a two-stage 
(Ivor Lewis) resection, a transhiatal resection, or a three-stage (McKeown) 
resection by either minimally invasive, hybrid, or open approaches (Table 2). 
Within this context, the unadjusted regression model did not identify 
preoperative T-stage or N-stage as predictors of OS. This model however identified 
increasing postoperative T and N stages as negative predictors of OS. Specifically, 










hazard ratio for all-cause death. In the adjusted preoperative model, staging was 
not associated with OS. In the adjusted postoperative model, pT stage was not 
associated with OS, yet pN stage was. 
The safest conclusion that can be drawn from our TNM data is that pN stage is a 
predictor of OS in resectable OAC. This was statistically evident despite 
confounding which may have arisen from the introduction of N3 in the 7th edition of 
the TNM Classification. The fact that pT stage was seen as a predictor of OS in the 
unadjusted analysis but not in the more reliable adjusted analysis, may be due to 
confounding factors in the unadjusted analysis. It is also possible that pT may not 
be as good predictor of OS in OAC as in SCC. Although the 7th edition was based 
on a strong international evidence base, which included more than 7 800 patients 
with esophageal cancer, it has been noted that these databases were limited in 
granularity and by their retrospective nature[16] 
4.4 - Neoadjuvant & adjuvant therapy 
In the current cohort, most patients (78.7%) received neoadjuvant 
chemotherapy, a well-established treatment modality which confers a survival 
benefit to patients with resectable esophageal cancer[1, 17]. A small minority 
received chemoradiotherapy (2.8%). No patients received neoadjuvant 
radiotherapy alone. Neoadjuvant treatment was not associated with OS in any 
regression model, and neither was adjuvant chemotherapy. Conversely, adjuvant 










worth noting here that only 15 patients received adjuvant radiotherapy and that all 
of these patients presented microscopically incomplete (R1) resections, therefore 
this (arguably) cannot be regarded as a reliable predictor based on this study. 
Neoadjuvant chemotherapy would be expected to increase OS. The absence of an 
observed association between neoadjuvant chemotherapy and OS may be due to 
the fact that most resections (85.3%) in this cohort were R0, with a relatively high 
mean LNY of 25.8, which may have decreased the positive effect valuation for this 
treatment. In addition, other implicated factor may have been that patients not 
submitted to neoadjuvant treatment generally presented earlier TNM stages (Table 
1), being less likely that this cohort would benefit from neoadjuvant chemotherapy 
due to overall good prognosis. 
In summary, this study has not identified neoadjuvant or adjuvant therapy as 
reliable predictors of OS in resectable OAC. Cohort size, staging differencesand 
good surgical outcomes may be responsible for the absence of associations. 
Frailty may also be a confounder, especially amongst patients who did not receive 
neoadjuvant therapy but proceeded directly to esophagectomy. Additionally, there 
may be variation in tumor biology which remains undetected, owing to the 
retrospective nature of this study. Finally, resection status may confound the 
relationship between adjuvant radiotherapy and OS, as this was administered to 










4.5 - Histopathological variables 
All four histopathological variables were associated with OS in at least one 
regression model. 
LNY was not associated with OS in the unadjusted model, however a LNY of 
≥35 was associated with OS in the postoperative model, with a HR of 0.22 when 
compared to a LNY <16. In a recent meta-analysis by Visser et al. a high LNY was 
identified as a positive prognostic factor for patients with esophageal cancer[18]. 
The authors recognized variation in the threshold between low and high LNY 
between studies and managed this heterogeneity by comparing the lowest to the 
highest LNY groups from each study[18]. They also recognize that although a high 
LNY enhances pathological staging, the therapeutic value of this practice is 
debatable[18]. Our findings would suggest that extended lymphadenectomy during 
esophagectomy is beneficial in terms of OS. In a recent international survey of 
experts by van Rijswijk et al.[19], Asian surgeons reportedly performed more 
extended cervical lymphadenectomies than their European colleagues. The 
authors highlighted the paucity of comparable data with regards to worldwide 
lymphadenectomy practice, in the context of various coexisting classification 
systems[19]. 
Histopathological tumor length was associated with OS both in the unadjusted, 
and in the adjusted postoperative models. Specifically, a tumor length of ≥25mm 










2.04 in the postoperative model. These findings are in keeping with multiple 
previous studies[20-24], although most studies included patients with SCC. 
Longitudinal tumor growth along the esophageal submucosa has been implicated 
as a predisposing factor towards lymph node metastasis and the development of 
micrometastases[20], thereby reducing survival. Interestingly, Rollins et al.[25] 
identified that tumor length on PET-CT and histopathology were significantly 
correlated, with a Pearson r = 0.5977[25]. Given this correlation, we would expect 
to observe an association between PET-CT tumor length and OS in our study. The 
lack of any association may be related to the SUVmax calculation pitfalls mentioned 
above, which would suggest that tumor length on PET-CT is an unreliable predictor 
of OS in resectable OAC. 
Tumor differentiation was associated with OS, albeit only in the unadjusted 
model. In this case, patients with well-to-moderately differentiated tumors and 
patients with poorly differentiated tumors had a HR for all-cause death of 2.86 and 
4.28 respectively vs. patients with complete response to neoadjuvant therapy. 
Tumor differentiation was not included in the adjusted postoperative model due to 
a very strong association with postoperative T stage. In a univariate and 
multivariate analysis of a predominantly OAC cohort, Griffiths et al.[21] also found 
that a lesser degree of differentiation was associated with poorer survival.  
A microscopically incomplete resection (R1) was associated with an all-cause 










models respectively. The impact of tumor differentiation and resection radicality on 
OS is expected and has been identified in previous studies[1, 21]. 
4.6 - Strengths and limitations 
The main strength of this study is the relative homogeneity of its cohort, with 
regards to histological cancer subtype, consistent use of PET-CT, and a common 
treatment pathway. Furthermore, regression analysis was performed according to 
three different models, thus arguably reducing the probability of a type-1 error, 
since any associations which appear only in one model are interpreted cautiously. 
The main limitation arises from the retrospective observational nature of this 
study and the relatively long study period of 10 years, during which surgical 
techniques and perioperative therapies are liable to evolve. Additionally, TNM 
staging has evolved and with the current study design it was not possible to 
ascertain which UICC TNM version was applied to each specific case. Ideally, with 
this knowledge, all cases could be retrospectively re-staged according to the latest 
version. In 2014, our centre implemented an ERAS (Enhanced Recovery After 
Surgery) protocol for all patients undergoing esophagectomy. Since ERAS involves 
standardization in patient preparation, and in the management of postoperative 
complications which may influence the timely progression to adjuvant treatment, 
this could have conceivably affected OS in a positive way for all patients. Finally, 
our dataset lacked the granularity required to accurately report cancer-related 










5 - Conclusions 
This study analyzed 16 variables against OS in patients with resectable OAC. 
There was no clear association between demographic or radiological variables and 
OS, although a higher PET-CT tumor SUVmax predicted worse outcomes in an 
adjusted model. There was also no obvious association between neoadjuvant or 
adjuvant treatments and OS. Postoperative N-stage, and the histopathological 
variables of LNY, tumor length, differentiation and resection radicality were all 
associated with OS. In conclusion, we would recommend that the esophageal 
cancer MDT does not exclude patients from curative treatment on the basis of age, 
sex, or PET-CT parameters, and that the discussion surrounding prognosis 
focuses on postoperative histopathological variables. 
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Figure 1: Study Flowchart 













Tables & figures 
Table 1: Preoperative variables 
Variable Value 
 Neoadjuvant therapy 
+ Surgery (n=207) 
Surgery alone 
(n=47) 
Median age at diagnosis in years (IQR) 66.0 (11.0) 73.0 (16.0) 
Sex (female / male) 33 / 174 
(15.9% / 84.1%) 
10/37 










Mean tumor length on PET-CT in mm 45.5 (SD=24.9) 20.0 (SD=20.5) 














































































































IQR: Interquartile range; N/A: Not available / not reported; PET-CT: Positron 
emission tomography with computed tomography; SD: Standard deviation; SUVmax: 













Table 2: Postoperative variables 
Variable Value 



































Mean histopathological tumor length (mm) 31.5 (SD=19.7) 
Mean number of lymph nodes retrieved 25.8 (SD=12.5) 
Mean number of lymph nodes positive for malignancy 2.2 (SD=3.9) 



































































































SD: Standard deviation; *In this analysis, the highest tumor grade (i.e. the lowest 
differentiation component) was quoted (e.g. “moderately-to-poorly” differentiated 













Table 3: Unadjusted Cox regression model (n=254) 
Factor 
 HR (95%CI) p-value 
Male (vs. Female) 1.17 (0.73-1.86) 0.521 
Age (1-year increments) 1.00 (0.98-1.02) 0.687 
Neoadjuvant chemotherapy 0.96 (0.62-1.48) 0.838 
Neoadjuvant radiotherapy 0.61 (0.19-1.93) 0.403 
Tumor SUVmax on PET-CT (≥15) 0.98 (0.96-1.00) 0.13 
Tumor length on PET-CT 1.00 (1.00-1.01) 0.254 
Preoperative T-stage 
T0 or T1 
T2 











































































  N/A 






















































Adjuvant chemotherapy 0.89 (0.62-1.27) 0.525 
Adjuvant radiotherapy 2.83 (1.86-4.30) <0.001 
R1 status 3.25 (2.18-4.86) <0.001 
HR: Hazard ratio for all-cause death; CI: Confidence interval; SUVmax: Maximal 
standardized radioisotope uptake value; PET-CT: Positron emission tomography with 












Table 4: Adjusted Cox regression models 




 HR (95% CI) p-value HR (95% CI) p-value 
Male (vs. Female) 0.95 (0.58-1.58) 0.857 1.03 (0.61-1.75) 0.9 
Age (1-year increments) 1 (0.98-1.03) 0.668 1 (0.98-1.02) 0.988 
Neoadjuvant chemotherapy 0.89 (0.5-1.58) 0.682 0.65 (0.36-1.19) 0.166 
Neoadjuvant radiotherapy 0.52 (0.13-2.17) 0.372 0.52 (0.11-2.48) 0.413 
Tumor SUVmax PET-CT (≥15) 0.55 (0.33-0.91) 0.02 0.79 (0.47-1.33) 0.377 
Tumor length PET-CT 1 (0.99-1.01) 0.486 1 (0.99-1.01) 0.787 
Preoperative T-stage 
T0 or T1 
T2 













































































































Adjuvant chemotherapy - - 0.77 (0.49-1.19) 0.231 
Adjuvant radiotherapy - - 1.49 (0.86-2.56) 0.151 
R1 status - - 2.33 (1.38-3.94) 0.002 
HR: Hazard ratio for all-cause death; CI: Confidence interval; SUVmax: Maximal 














• No pre-treatment PET-CT or TL reported: n=40 
• Death within 30 postoperative days: n=5 
• Tumor other than adenocarcinoma: n=46 
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